Australia markets closed
  • ALL ORDS

    6,696.50
    +29.00 (+0.43%)
     
  • AUD/USD

    0.6470
    +0.0011 (+0.18%)
     
  • ASX 200

    6,496.20
    +26.80 (+0.41%)
     
  • OIL

    78.00
    +1.29 (+1.68%)
     
  • GOLD

    1,644.20
    +10.80 (+0.66%)
     
  • BTC-AUD

    31,172.37
    +1,490.04 (+5.02%)
     
  • CMC Crypto 200

    460.67
    +1.53 (+0.33%)
     

Integra LifeSciences (IART) is a Top-Ranked Growth Stock: Should You Buy?

·2-min read

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Integra LifeSciences (IART)

Headquartered in Plainsboro, NJ, Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Orthopedics and Tissue Technologies (OTT).

IART is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 4.1% year-over-year for the current fiscal year, with sales growth of 3.3%.

Five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $3.31 per share for 2022. IART boasts an average earnings surprise of 11.8%.

On a historic basis, Integra LifeSciences has generated cash flow growth of 13.6%, and is expected to report cash flow expansion of 13.2% this year.

IART should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.